Blood phosphatidylethanol measurements indicate GLP ‐1 receptor stimulation causes delayed decreases in alcohol consumption
Alcohol, Clinical and Experimental Research · 2025-05 · 49 (5) · 1161-1165
DOI: 10.1111/acer.70041 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alcohol, Clinical and Experimental Research, online erschienen am 23.03.2025. Verfasst von Mathias E Jensen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatric Centre Copenhagen, Frederiksberg, University of Copenhagen, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Exenatide, Alcohol Drinking, Glycerophospholipids, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The investigation of glucagon‐like peptide 1 (GLP‐1) receptor agonists (GLP‐1RA) as a potential treatment for individuals with alcohol use disorder (AUD) and obesity is currently underway. In this secondary analysis of a randomized placebo‐controlled trial, we included AUD patients with comorbid obesity and assessed the effect of the GLP‐1RA exenatide versus placebo on alcohol consumption as measured by the alcohol biomarker phosphatidylethanol (PEth).
Methods
Thirty AUD patients (9 females, 21 males), with an average age of 53 years and a body mass index (BMI) of at least 30 kg/m 2 , were included in this secondary analysis. Blood samples for PEth were collected at baseline and at weeks 4, 12, 20, and 26. The effect of time and treatment on PEth levels was analyzed using a baseline‐adjusted linear mixed model.
Results
A significant interaction between time and treatment was observed at Week 26, with PEth levels reduced by −0.9 μ mol/L in the exenatide group compared to placebo (95% CI [−1.6 to −0.1], p = 0.03). However, the difference in PEth blood levels between the exenatide and placebo groups was not significant at earlier time points.
Conclusion
This secondary analysis indicates that exenatide has a delayed yet significant impact on alcohol consumption in individuals with AUD and obesity, as assessed by PEth levels. These findings warrant further investigation, which is currently underway (NCT05895643).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Psychiatric Centre Copenhagen, Frederiksberg, University of Copenhagen, Copenhagen, Denmark.
- Department of Biochemistry and Immunology, University Hospital of Southern Denmark, Vejle, Denmark.
- Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Clinical Research, Steno Diabetes Center Copenhagen, University of Copenhagen, Herlev, Denmark.
- Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
ORCID-Profile: Mathias E Jensen, Anders Fink-Jensen
Zitieren
APA
Jensen, M. E., Klausen, M. K., Bergmann, M. L., Knudsen, G. M., Vilsbøll, T., Stove, C., & Fink-Jensen, A. (2025). Blood phosphatidylethanol measurements indicate GLP ‐1 receptor stimulation causes delayed decreases in alcohol consumption. Alcohol, Clinical and Experimental Research, 49(5), 1161-1165. https://doi.org/10.1111/acer.70041
Vancouver
Jensen ME, Klausen MK, Bergmann ML, Knudsen GM, Vilsbøll T, Stove C, et al. Blood phosphatidylethanol measurements indicate GLP ‐1 receptor stimulation causes delayed decreases in alcohol consumption. Alcohol, Clinical and Experimental Research. 2025;49(5):1161-1165. doi:10.1111/acer.70041
BibTeX
@article{Jensen2025,
author = {Jensen, Mathias E and Klausen, Mette K and Bergmann, Marianne L and Knudsen, Gitte M and Vilsbøll, Tina and Stove, Christophe and Fink-Jensen, Anders},
title = {Blood phosphatidylethanol measurements indicate GLP ‐1 receptor stimulation causes delayed decreases in alcohol consumption},
journal = {Alcohol, Clinical and Experimental Research},
year = {2025},
volume = {49},
number = {5},
pages = {1161--1165},
doi = {10.1111/acer.70041}
}
EUVIMED